Abstract
Among the immunotherapies, the CAR-T cell therapy has been standing out in the past few years, given the promising results obtained for hematologic malignancies. The insertion of a CAR (Chimeric Antigen Receptor) molecule in the T cells provides an antigen specific and MHC (Major Histocompatibility Complex) independent antigen recognition. The CAR-T cell products currently approved for cl…